Quality of Research
School of Medicine
Research Assessment Exercise (2008)
|Unit of Assessment||Staff submitted (FTE)||By percentage, research activity in the submission judged to reach quality standard|
|Cancer Studies (A2)||26.60||4||3||2||1||UC|
(Overall quality profile in blocks of 5%)
Research Profile: Cancer Studies
The Cancer Interdisciplinary Research Group is expanding its established areas of international excellence in basic and clinical research to build stronger translational bridges to clinical practice in selected fields.
Basic cancer research focuses on two key features of the cancer cell – genomic instability and disruption of cell proliferation. Researchers in the School of Medicine work with colleagues in Biosciences on genome instability, which affects the origins of tumours, the progress of cancers and their resistance to therapy. The research group is a world leader on telomeres – genetic devices which control cell division and can trigger cancer when they do not function properly.
The School has made successful breakthroughs in breast cancer research.
Major core awards have been won for translational research projects of national significance, including the Wales Cancer Bank, the Wales Cancer Trials Unit and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). The aims of the Cancer Research UK Experimental Cancer Medicine Centre are to build on Cardiff’s research strengths in selected cancers, identifying the molecular basis for their diagnosis and prognosis as well as new targets for treatment. A key aim is to apply to solid tumours a highly-successful strategy for leukaemia research which has taken new treatments from cell testing through to full clinical trials.
Research in breast cancer has brought about a major breakthrough, which will spare around 20,000 women each year in the UK the need for potentially debilitating armpit surgery to stop the spread of the disease. The group is also developing new treatments to target the invasion and spread of prostate and breast cancers. Cardiff researchers were the first to identify the genes for tuberous sclerosis and are now trialling what could be one of the world’s first treatments developed from our new genetic knowledge.
The group has significantly expanded its postgraduate research numbers. This has been achieved by increased success in winning externally-funded studentships from Cancer Charities and Research Councils, supplemented by a School-based scheme to increase capacity by adding matching internal funds.